Skip to Main Content

In an unusual move, the chair of a Food and Drug Administration panel is defying a recommendation that his own panel made last week to endorse a powerful opioid painkiller, because he believes the drug represents a “danger” to public health. And to make sure his views are known, Dr. Raeford Brown, the panel chair, conveyed his concerns in a letter on Thursday to FDA officials.

At issue is Dsuvia, which the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee last Friday voted 10-to-3 to recommend for combating moderate-to-severe acute pain, but only for adults in medically supervised settings. The drug is a tablet version of an opioid that is marketed for intravenous delivery, but is administered under the tongue using a specially developed, single-dose applicator.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Opioids should be prescribed with acupuncture which is a non-invasive procedure that induces pain reduction and addiction.

  • They are clearly motivated by something other than safety and well being- other than their own. Try asking the people that are USING PAINKILLERS.

Comments are closed.